We found that thyroid carcinomas, parathyroid adenomas, pancreatic neuroendocrine tumours, renal clear cell carcinomas, and lymphomas exhibited strong CALCRL expression in a high percentage of specimens. This evidence concerns the gene CALCRL and clear cell renal carcinoma.